Literature DB >> 20048177

Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.

Mubarak Al-Mansour1, Joseph M Connors, Randy D Gascoyne, Brian Skinnider, Kerry J Savage.   

Abstract

PURPOSE Prior observations suggest a higher risk of transformation of nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) to aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL), than in classical Hodgkin's lymphoma. We evaluated the frequency of transformation in all patients diagnosed with NLPHL at the British Columbia Cancer Agency with long-term follow-up. PATIENTS AND METHODS The Lymphoid Cancer Database of the British Columbia Cancer Agency was searched to identify all patients diagnosed with NLPHL between 1965 and 2006. After pathologic review, 95 patients with NLPHL were confirmed. Results Patients with NLPHL had the following characteristics at diagnosis: median age of 37 years, 73% male, and 68% stage I or II disease. With a median follow-up time for living patients of 6.5 years (range, 2.5 to 33 years), 13 patients (14%) experienced transformation to aggressive lymphoma (median time to transformation, 8.1 years; range, 0.35 to 20.3 years). The actuarial risk of transformation to aggressive lymphoma was 7% and 30% at 10 and 20 years, respectively. Transformation was more likely in patients with initial splenic involvement (P = .006) at the time of diagnosis of NLPHL. The 10-year progression-free and overall survival rates in patients with transformed lymphoma were 52% and 62%, respectively. CONCLUSION The risk of transformation in patients with NLPHL to DLBCL is substantial and underappreciated. Because transformation can occur years after the primary diagnosis of NLPHL, long-term follow-up of these individuals is necessary to accurately estimate the risk of development of secondary DLBCL.

Entities:  

Mesh:

Year:  2010        PMID: 20048177     DOI: 10.1200/JCO.2009.24.9516

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  34 in total

1.  Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.

Authors:  D A Eichenauer; H Goergen; A Plütschow; D Wongso; K Behringer; S Kreissl; I Thielen; T Halbsguth; P J Bröckelmann; M Fuchs; B Böll; B von Tresckow; P Borchmann; A Engert
Journal:  Leukemia       Date:  2015-11-20       Impact factor: 11.528

2.  Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  S Hartmann; B Schuhmacher; T Rausch; L Fuller; C Döring; M Weniger; A Lollies; C Weiser; L Thurner; B Rengstl; U Brunnberg; M Vornanen; M Pfreundschuh; V Benes; R Küppers; S Newrzela; M-L Hansmann
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

3.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2010-06-02       Impact factor: 0.196

Review 4.  [Update on nodular lymphocyte predominant Hodgkin's lymphoma and related lesions].

Authors:  S Hartmann; M-L Hansmann
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

5.  Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.

Authors:  Julien Lazarovici; Peggy Dartigues; Pauline Brice; Lucie Obéric; Isabelle Gaillard; Mathilde Hunault-Berger; Florence Broussais-Guillaumot; Emmanuel Gyan; Serge Bologna; Emmanuelle Nicolas-Virelizier; Mohamed Touati; Olivier Casasnovas; Richard Delarue; Frédérique Orsini-Piocelle; Aspasia Stamatoullas; Jean Gabarre; Luc-Matthieu Fornecker; Thomas Gastinne; Fréderic Peyrade; Virginie Roland; Emmanuel Bachy; Marc André; Nicolas Mounier; Christophe Fermé
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

6.  [Nodular lymphocyte-dominant Hodgkin's lymphoma : LP cells show recurrent mutations in DUSP2, SGK1 and JUNB].

Authors:  S Hartmann
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

Review 7.  Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.

Authors:  Dennis A Eichenauer; Andreas Engert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.

Authors:  Lianna J Marks; Qinglin Pei; Rizvan Bush; Allen Buxton; Burton Appel; Kara M Kelly; Cindy L Schwartz; Debra L Friedman
Journal:  Pediatr Blood Cancer       Date:  2018-09-14       Impact factor: 3.167

9.  Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen Buxton; Suzanne L Wolden; David C Hodgson; James B Nachman
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

10.  Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Jean François Grellier; Laetitia Vercellino; Thierry Leblanc; Pascal Merlet; Catherine Thieblemont; Pierre Weinmann; Marie-Elisabeth Toubert; Nathalie Berenger; Josette Brière; Pauline Brice
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-26       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.